Sepsis therapeutics market seen reaching $6.92 billion by 2030

The global sepsis therapeutics market is projected to grow from $4.82 billion in 2026 to $6.92 billion by 2030, according to The Business Research Company. The report points to rising infectious disease rates, new treatment development and expanding critical care capacity as the main growth drivers.

Why it matters: - Sepsis remains a life-threatening condition that needs faster diagnosis and more effective treatment. - Market growth signals rising demand for therapies that can reduce organ failure and improve survival outcomes. - The projected expansion reflects wider pressure on hospitals, critical care systems and infection management worldwide.

What happened: - The Business Research Company released a new report on the global sepsis therapeutics market on August 26, 2026. - The market is estimated at $4.82 billion in 2026, up from $4.39 billion in 2025. - The report forecasts the market will reach $6.92 billion by 2030. - The forecast implies a 9.5% CAGR through the forecast period. - A free sample report is available here. - The full report is available here.

The details: - Sepsis therapeutics include medications and medical interventions used to treat sepsis caused by the body’s overwhelming response to infection. - These therapies aim to control the infection source, support vital organ function, manage inflammation and prevent organ failure. - The report says historic growth has been supported by limited access to advanced treatment options, high rates of hospital-acquired infections, reliance on traditional antibiotics, better sepsis awareness and weak critical care infrastructure in some regions. - Forecast growth is tied to novel antibiotic classes, biologic therapies, more research funding, expanded critical care hospital units, better patient monitoring tools and wider use of telemedicine and digital health platforms. - The report flags rising use of injectable sepsis treatments, broader ICU capacity, advanced broad-spectrum antibiotics, earlier diagnosis and more remote healthcare services as key trends. - One growth driver is the rising prevalence of infectious diseases worldwide. - The report links climate change to the spread of disease carriers such as mosquitoes and the broader spread of infections including malaria and dengue fever. - A January 2023 National Library of Medicine report said infectious diseases cause more than 52 million deaths each year and put about half the world’s population at risk. - The same report said nearly 14 million children under five die annually, with 70% of those deaths tied to preventable diseases through vaccination.

Between the lines: - The market outlook suggests sepsis care is moving beyond standard antibiotics toward a mix of new drug classes, biologics and closer monitoring. - Regional growth patterns point to mature demand in North America and faster expansion in Asia-Pacific as healthcare access and critical care infrastructure improve. - The emphasis on telemedicine and digital health signals that sepsis management is becoming more connected to broader hospital workflow and remote monitoring tools.

What's next: - The report expects North America to keep the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics, trend analysis and updated graphics and tables. - More information is available through the company’s LinkedIn page.

The bottom line: - Sepsis therapeutics is a growing market because infection rates are rising, critical care is expanding and drug development is advancing.